Revision: Feb. 1, 2024, 9:02 a.m.
Health and Human Services
January 31, 2024
2024-0405s
05/06
Amendment to SB 399-FN
Amend the bill by replacing sections 2 and 3 with the following:
2 Accident and Health Insurance. Amend RSA 415:6-v to read as follows:
415:6-v Coverage for Blood Lead Testing. Each insurer that issues or renews any individual policy, plan, or contract of accident or health insurance providing benefits for medical or hospital expenses shall provide to persons covered by such insurance who are residents of this state coverage for the costs of blood lead testing conducted pursuant to RSA 130-A:5-a. Benefits provided under this section shall not be subject to any [greater] co-payment, deductible, or coinsurance [than any other similar benefits provided by the insurer]. Benefits provided under this section shall include any follow-up blood lead testing that is necessary to complete the preventive screening when the initial blood lead testing indicates an elevated blood lead level or is inconclusive.
3 Accident and Health Insurance. Amend RSA 415:18-aa to read as follows:
415:18-aa Coverage for Blood Lead Testing. Each insurer that issues or renews any policy of group or blanket accident or health insurance providing benefits for medical or hospital expenses shall provide to each group, or to the portion of each group comprised of certificate holders of such insurance who are residents of this state, coverage for the costs of blood lead testing conducted pursuant to RSA 130-A:5-a. Benefits provided under this section shall not be subject to any [greater] co-payment, deductible, or coinsurance [than any other similar benefits provided by the insurer]. Benefits provided under this section shall include any follow-up blood lead testing that is necessary to complete the preventive screening when the initial blood lead testing indicates an elevated blood lead level or is inconclusive.
2024-0405s
AMENDED ANALYSIS
This bill provides that health insurance coverage for blood lead testing shall not be subject to a co-payment, deductible, or coinsurance. The bill also requires coverage for follow-up blood testing that is necessary to complete the preventive screening when the initial blood testing indicates an elevated blood lead level or is inconclusive.